New ARV with ‘fewer side effects’

Organisation: Position: Deadline Date: Location:

A new antiretroviral drug is set to make HIV treatment compliance easier for patients. The antiretroviral which has a chemical component known as Dolutegravir was unveiled on the second day of the 21st International Aids Conference in Durban.

The drug manufactured by Aspen Pharmacare Holdings is used in much smaller quantities than conventional antiretrovirals.

Aspen’s Spokesperson Stavros Nicolaou says the drug, which was launched two months ago, is used on its own with a combination of  two other ARVs.

“The compound is used in much smaller quantities than your conventional antiretroviral, has a better safety profile and offers a number of advantages to existing treatment.”

Nicolaou says going forward the company aims to combine the ARVs into a single pill.

Full SABC News report

IOL Report: Aids champions may help make new drugs in Africa

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.